论文部分内容阅读
我们于1995年6月～1996年12月,应用胸腺因子D(Thymofactor D简写TFD)与单磷酸阿糖腺苷(arabin ofuranosyl-adenine monophoate 简写ARA-AMP)联合治疗(Hepatit B Virus简写HBV)复制指标阳性患者65例,并与同期单纯应用Ara-AMP的31例进行对照。结果显示,联合治疗组对HBV复制指标阴转效果较好,无明显毒副作用,报告如下。 1 资料与方法 1.1 临床资料:全部病例均为我院住院患者,符合1995年5月北京第五次全国传染病寄生虫学术会议修订的诊断标准。应用TFD与ARA-AMP联合治疗的为Ⅰ组:同期单纯应用ARA-AMP者为Ⅱ组。两组病例治疗前均经两次以上检测HBsAg、HBeAg和(或)HBV-DNA阳性。
In June 1995 ~ December 1996, we used Thymofactor D (abbreviated TFD) combined with arabinofuranosyl-adenine monophoate (ARA-AMP) to treat Hepatit B Virus (HBV) replication 65 patients with positive indicators, and compared with the same period the simple application of Ara-AMP in 31 cases were compared. The results showed that the combination therapy group on HBV replication indicators of negative conversion effect is better, no significant side effects, the report is as follows. 1 Materials and Methods 1.1 Clinical data: All cases were hospitalized patients in our hospital, in line with the 1995 May Beijing Fifth National Conference on Infectious Diseases Parasitology revised diagnostic criteria. Application of TFD and ARA-AMP combination treatment for the Ⅰ group: the same period the simple application of ARA-AMP were Ⅱ group. Two groups of patients were tested twice before HBsAg, HBeAg and (or) HBV-DNA positive.